![Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: a 24-week Observational Study](http://www.ia-grp.com/wp-content/plugins/revslider/public/assets/assets/transparent.png)
![](http://www.ia-grp.com/wp-content/uploads/2017/07/ORANGE-SLIDER-SHAPE-1.1.png)
Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: a 24-week Observational Study
Published:
July 16, 2020
Publication:
Osteoarthritis and Cartilage
Authors:
MA Mont, JA Carrino, F Shafiei, M Nemeth, A Burr, T Yamabe, L Viktrup, CR West, MT Brown, K Verburg